Behind every medicine is a story—a story of people who make it possible. In the series Where Craft Meets, Daiichi Sankyo explores and celebrates the people behind our medicines and shares how our unique crafts contribute to our collective mission to help patients.
Early breast cancer is often treated with curative intent—but there is still more to learn about treatment response and recurrence risk. Explore how researchers are following the science earlier in the disease journey to address unmet needs and advance new possibilities for patients.
In certain cancers, HER2 becomes overexpressed or uncontrolled, driving tumors to develop quickly. As our understanding of HER2 and its role deepens, its relevance across endometrial, ovarian and other gynecologic tumors has become…
My decision to devote my career to oncology is deeply personal. During my senior year in college, my father was diagnosed with cholangiocarcinoma, or bile duct cancer. As one of his caregivers…
Not all breast cancers are the same. This is particularly true about metastatic breast cancer versus early-stage breast cancer in terms of how the disease spreads, its prognosis, treatment options, and even the patient journey.
Business development is the craft of making connections. Whether with other companies or within our organization, we need to build those bonds that allow us to be successful.
Cancer research and development is a dynamic and ever-evolving field. One significant area of focus is the role of HER2.